{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:11:07Z","timestamp":1779149467565,"version":"3.51.4"},"reference-count":24,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"Abstract<\/jats:title>\n \n Context<\/jats:title>\n Adrenocorticotropic hormone (ACTH)\u2013dependent Cushing syndrome (CS) is associated with a markedly increased risk of venous thromboembolism (VTE), yet thromboprophylaxis strategies remain inconsistent across clinical practice. In 2019, our center introduced routine oral rivaroxaban prophylaxis (10 mg once daily) for all patients with ACTH-dependent CS.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety and effectiveness of routine rivaroxaban prophylaxis in ACTH-dependent CS.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n We retrospectively reviewed 70 adults with ACTH-dependent CS managed between 2012 and 2025 (29 pre-2019 and 41 post-2019) to compare VTE incidence before and after the introduction of rivaroxaban.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n There were no differences in baseline characteristics between the 2 groups. Cushing disease (ie, secondary to a pituitary corticotroph adenoma) was the most common subtype (26\/29 pre-2019 and 34\/41 post-2019). Among patients without routine prophylaxis (pre-2019), 4 patients (13.8%) developed 6 VTE events, occurring both pre- and postoperatively. In the post-2019 cohort, 5 patients experienced 7 VTE events before endocrine assessment and before rivaroxaban could be initiated. Two had recurrent VTE and were already receiving long-term treatment-dose anticoagulation; therefore, 39 of the 41 proceeded with rivaroxaban prophylaxis. No major or minor bleeding complications were observed. Hematological parameters remained stable, and all patients completed the prescribed prophylaxis course (median duration: 7.9 months).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In our cohort, VTE incidence was 13.8% without prophylaxis and did not occur after the introduction of routine rivaroxaban. Prophylactic oral rivaroxaban in ACTH-dependent CS was safe and effective in preventing new, recurrent, perioperative, and postoperative VTE events, supporting its early initiation at diagnosis and continuation through the peri- and postoperative period.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/clinem\/dgag014","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T12:46:50Z","timestamp":1768394810000},"page":"e1477-e1484","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone\u2013dependent Cushing syndrome"],"prefix":"10.1210","volume":"111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0490-7836","authenticated-orcid":false,"given":"Zin","family":"Htut","sequence":"first","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aastha","family":"Mundhra","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0758-7839","authenticated-orcid":false,"given":"Katharine","family":"Lazarus","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Imperial College London , London W12 0NN ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1185-2762","authenticated-orcid":false,"given":"Niamh","family":"Martin","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Imperial College London , London W12 0NN ,","place":["UK"]},{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust , London W12 0HS ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Papadopoulou","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust , London W12 0HS ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7112-2756","authenticated-orcid":false,"given":"Karim","family":"Meeran","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Imperial College London , London W12 0NN ,","place":["UK"]},{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust , London W12 0HS ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5914-9318","authenticated-orcid":false,"given":"Florian","family":"Wernig","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Imperial College London , London W12 0NN ,","place":["UK"]},{"name":"Department of Endocrinology, Imperial College Healthcare NHS Trust , London W12 0HS ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"issue":"9522","key":"2026051819570812100_dgag014-B1","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S0140-6736(06)68699-6","article-title":"Cushing's syndrome","volume":"367","author":"Newell-Price","year":"2006","journal-title":"Lancet"},{"issue":"6","key":"2026051819570812100_dgag014-B2","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1210\/jc.2012-3582","article-title":"Multisystem morbidity and mortality in Cushing's syndrome: a cohort study","volume":"98","author":"Dekkers","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2026051819570812100_dgag014-B3","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1210\/clinem\/dgaa291","article-title":"Excess morbidity persists in patients with Cushing's disease during long-term remission: a Swedish nationwide study","volume":"105","author":"Papakokkinou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026051819570812100_dgag014-B4","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s12020-009-9186-y","article-title":"Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers","volume":"36","author":"Kastelan","year":"2009","journal-title":"Endocrine"},{"issue":"2","key":"2026051819570812100_dgag014-B5","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03345709","article-title":"Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels","volume":"32","author":"Erem","year":"2009","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"2026051819570812100_dgag014-B6","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"van der Pas","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051819570812100_dgag014-B7","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/cen.12094","article-title":"Hypercoagulability in Cushing's syndrome: prevalence, pathogenesis and treatment","volume":"78","author":"van der Pas","year":"2013","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2026051819570812100_dgag014-B8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13023-022-02320-x","article-title":"Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN)","volume":"17","author":"van Haalen","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"2026051819570812100_dgag014-B9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing's disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2026051819570812100_dgag014-B10","doi-asserted-by":"crossref","DOI":"10.1530\/EC-23-0557","article-title":"Patients with Cushing's syndrome suffer from provoked venous thromboembolism and are anticoagulated in various patterns","volume":"13","author":"Bryk-Wiazania","year":"2024","journal-title":"Endocr Connect"},{"issue":"1","key":"2026051819570812100_dgag014-B11","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1038\/s41598-023-30070-8","article-title":"Prevalence of perioperative asymptomatic venous thromboses of the lower extremity in 30 consecutive patients undergoing transsphenoidal surgery for Cushing's disease","volume":"13","author":"Huckhagel","year":"2023","journal-title":"Sci Rep"},{"issue":"2","key":"2026051819570812100_dgag014-B12","doi-asserted-by":"crossref","first-page":"bvz033","DOI":"10.1210\/jendso\/bvz033","article-title":"Hypercoagulability in Cushing syndrome, prevalence of thrombotic events: a large, single-center, retrospective study","volume":"4","author":"Suarez","year":"2020","journal-title":"J Endocr Soc"},{"issue":"4","key":"2026051819570812100_dgag014-B13","doi-asserted-by":"crossref","first-page":"M11","DOI":"10.1530\/EJE-15-0198","article-title":"Adverse effects of glucocorticoids: coagulopathy","volume":"173","author":"Coelho","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2026051819570812100_dgag014-B14","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1210\/jc.2011-1661","article-title":"Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study","volume":"96","author":"Stuijver","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026051819570812100_dgag014-B15","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.wneu.2024.08.090","article-title":"Venous thromboembolism and prevention strategies in patients with Cushing's disease: a systematic review","volume":"191","author":"White","year":"2024","journal-title":"World Neurosurg"},{"issue":"3","key":"2026051819570812100_dgag014-B16","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous Cushing's syndrome: a position statement","volume":"192","author":"Isand","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"(05|5)","key":"2026051819570812100_dgag014-B17","first-page":"365","article-title":"Coagulation profile in patients with different etiologies for Cushing syndrome: a prospective observational study","volume":"49","author":"Tirosh","year":"2017","journal-title":"Horm Metab Res"},{"issue":"8","key":"2026051819570812100_dgag014-B18","first-page":"3662","article-title":"Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome","volume":"87","author":"Boscaro","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026051819570812100_dgag014-B19","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11102-014-0600-y","article-title":"Perioperative thromboprophylaxis in Cushing's disease: what we did and what we are doing?","volume":"18","author":"Barbot","year":"2015","journal-title":"Pituitary"},{"issue":"9","key":"2026051819570812100_dgag014-B20","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/jcm14092914","article-title":"Challenges and opportunities of direct oral anticoagulant (DOAC) therapy in complex clinical scenarios: a comprehensive review and practical guide","volume":"14","author":"Miceli","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"2026051819570812100_dgag014-B21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s11154-010-9143-3","article-title":"The diagnosis of Cushing's syndrome","volume":"11","author":"Carroll","year":"2010","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2026051819570812100_dgag014-B22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1210\/er.2015-1042","article-title":"Pituitary apoplexy","volume":"36","author":"Briet","year":"2015","journal-title":"Endocr Rev"},{"issue":"1","key":"2026051819570812100_dgag014-B23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/ejendo\/lvad176","article-title":"High prevalence of venous thrombotic events in Cushing's syndrome: data from ERCUSYN and details in relation to surgery","volume":"190","author":"Isand","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2026051819570812100_dgag014-B24","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1210\/js.2018-00278","article-title":"Is VTE prophylaxis necessary on discharge for patients undergoing adrenalectomy for Cushing syndrome?","volume":"3","author":"Babic","year":"2019","journal-title":"J Endocr Soc"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag014\/66424036\/dgag014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/6\/e1477\/66424036\/dgag014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/6\/e1477\/66424036\/dgag014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T23:57:13Z","timestamp":1779148633000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/6\/e1477\/8426686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag014","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,1,16]]}}}